Clinical Trial Update: Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) [Phase 3]

View source ↗

Summary

Phase 3 study evaluating intravitreal aflibercept for nonproliferative diabetic retinopathy has completed with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonproliferative Diabetic Retinopathy

Drugs mentioned

• Aflibercept (Aflibercept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Nonproliferative Diabetic Retinopathy | Phase 3 | Status: COMPLETED | Results posted: 2019-11-21